Pulmonary function tests (PFTs) are invaluable tools in the diagnosis, monitoring, and management of respiratory diseases. The interpretation of these tests, however, can be complex and challenging, necessitating a comprehensive understanding for accurate clinical application.
PFTs primarily assess three parameters: lung volumes, airflow, and gas exchange. Forced Vital Capacity (FVC), Forced Expiratory Volume in 1 second (FEV1), and their ratio (FEV1/FVC) are the key indicators of airflow. Total Lung Capacity (TLC), Residual Volume (RV), and Functional Residual Capacity (FRC) depict lung volumes. Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) measures gas exchange.
Spirometry is the cornerstone of PFTs. Normal FEV1/FVC ratio is above 0.7. A decreased ratio suggests obstructive disease, while normal or increased ratio with decreased volumes indicates restrictive pattern. The severity of obstruction or restriction is classified based on FEV1 or FVC percentages of predicted values.
Increased RV and FRC suggest air trapping, common in obstructive diseases. Decreased TLC indicates restrictive disease. A reduced DLCO points towards impaired gas exchange, seen in interstitial lung disease and pulmonary vascular disorders. However, it might be normal in pure airway diseases like asthma.
Interpretation of PFTs should always be integrated with clinical context and other investigations. For instance, a normal DLCO in a patient with reduced volumes and FEV1/FVC ratio may favor a diagnosis of asthma over COPD. Conversely, a reduced DLCO in a patient with normal spirometry could suggest early interstitial lung disease.
Interpreting PFTs is a vital skill for healthcare professionals involved in respiratory care. A thorough understanding of the basic parameters, coupled with an ability to integrate these results with clinical context, can greatly enhance diagnostic accuracy and patient management.
1.
FDA Declines to Approve Achieve Life Sciences' Smoking-cessation Drug
2.
Uncovered biology underlies a novel drug used to treat triple-negative breast cancer.
3.
Chemotherapy damage to non-cancer cells may be the cause of breast cancer recurrence.
4.
Never in a million years did I think I'd have to limit my chemotherapy.
5.
Treating Depression: Crucial for Recovery From Fibromyalgia
1.
HCC in Melanoma: Role of HCC Codes and Moderate Whole Body Hyperthermia
2.
Clinical Analysis of Prostate Cancer
3.
Sorafenib: Understanding the science behind a powerful cancer drug
4.
Early-Onset GI Cancers: Screening, AI Innovations & Research Advances 2025
5.
Comprehensive Breakthroughs in Oncology for Better Care
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Understanding the Evolution in Lung Cancer- An Initiative from Manipal Hospitals: Further Discussion
2.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
3.
A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
4.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
5.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation